Background: Cerebrospinal fluid (CSF) biomarkers (Aβ peptides and tau proteins) improved the diagnosis of Alzheimer’s disease (AD) in research and clinical settings. We previously described the PLM-scale (Paris-Lille-Montpellier study), which combines Aβ42, tau, and phosphorylated ptau(181) biomarkers in an easy to use and clinically relevant way. The purpose of this work is to evaluate an optimized PLMR-scale (PLM ratio scale) that now includes the Aβ42/Aβ40 ratio to detect AD versus non-AD (NAD) participants in clinical routine of memory centers.Methods: Both scales were compared using 904 participants with cognitive impairment recruited from two independent cohorts (Mtp-1 and Mtp-2). The CSF Aβ42/Aβ40 ratio was measured systematically in...
Introduction: In this study of preclinical Alzheimer’s disease (AD) we assessed the added diagnostic...
Background:To enhance the accuracy of clinical diagnosis for Alzheimer’s disease (AD), pre-mortem bi...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...
International audienceBackground: Cerebrospinal fluid (CSF) biomarkers (Aβ peptides and tau proteins...
<p>Background: Cerebrospinal fluid (CSF) biomarkers (Aβ peptides and tau proteins) improved the diag...
Introduction: The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ), tau and phosphorylated tau (p...
In the last decades, an important role of cerebrospinal fluid (CSF) biomarkers for Alzheimer disease...
OBJECTIVE: The diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (...
Abstract The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Ta...
Abstract Background Cerebrospinal fluid (CSF) biomarkers have been used to increase the evidence of ...
INTRODUCTION: The relevance of the cerebrospinal fluid (CSF) biomarkers for the diagnosis of Alzheim...
peer reviewedBACKGROUND: The incoming disease-modifying therapies against Alzheimer's disease (AD) r...
Background: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD)...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...
International audienceThe cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ...
Introduction: In this study of preclinical Alzheimer’s disease (AD) we assessed the added diagnostic...
Background:To enhance the accuracy of clinical diagnosis for Alzheimer’s disease (AD), pre-mortem bi...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...
International audienceBackground: Cerebrospinal fluid (CSF) biomarkers (Aβ peptides and tau proteins...
<p>Background: Cerebrospinal fluid (CSF) biomarkers (Aβ peptides and tau proteins) improved the diag...
Introduction: The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ), tau and phosphorylated tau (p...
In the last decades, an important role of cerebrospinal fluid (CSF) biomarkers for Alzheimer disease...
OBJECTIVE: The diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (...
Abstract The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Ta...
Abstract Background Cerebrospinal fluid (CSF) biomarkers have been used to increase the evidence of ...
INTRODUCTION: The relevance of the cerebrospinal fluid (CSF) biomarkers for the diagnosis of Alzheim...
peer reviewedBACKGROUND: The incoming disease-modifying therapies against Alzheimer's disease (AD) r...
Background: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD)...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...
International audienceThe cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ...
Introduction: In this study of preclinical Alzheimer’s disease (AD) we assessed the added diagnostic...
Background:To enhance the accuracy of clinical diagnosis for Alzheimer’s disease (AD), pre-mortem bi...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...